WO2026104987 - REMIBRUTINIB FOR USE IN THE TREATMENT OF MYASTHENIA GRAVIS
National phase entry is expected:
Publication Number
WO/2026/104987
Publication Date
21.05.2026
International Application No.
PCT/IB2025/061515
International Filing Date
11.11.2025
Title **
[English]
REMIBRUTINIB FOR USE IN THE TREATMENT OF MYASTHENIA GRAVIS
[French]
REMIBRUTINIB POUR UTILISATION DANS LE TRAITEMENT DE LA MYASTHÉNIE GRAVE
Applicants **
NOVARTIS AG
Inventors
CENNI, Bruno
KIESEIER, Bernd C.
LOSEN, Mario René
MANÉ DAMAS, Marina
MARTÍNEZ MARTÍNEZ, Maria Pilar
PUTZKI, Norman
SU, Wendy
WILLI, Roman
Priority Data
63/719,892
13.11.2024
US
63/882,508
16.09.2025
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2731 | |
| EPO | Filing, Examination, Granting | 15426 | |
| Japan | Filing, Examination, Granting | 2525 | |
| South Korea | Filing, Examination, Granting | 2858 | |
| USA | Filing, Examination, Granting | 7340 |
Total:
30,880
Contact Us
Abstract[English]
Described herein are methods of treating gMG with the BTK inhibitor remibrutinib or a pharmaceutically acceptable salt thereof.[French]
La présente invention concerne des méthodes de traitement de la MGg avec l'inhibiteur de BTK remibrutinib ou un sel pharmaceutiquement acceptable de celui-ci.